Actively Recruiting
Phase 1 Evaluation of Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of ABBV-859 in Healthy Adults
Led by AbbVie · Updated on 2026-08-03
64
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating ABBV-859 in healthy adult volunteers to study its safety, tolerability, how it moves through the body pharmacokinetics, and immune response after single increasing doses. This is a Phase 1 clinical trial aimed at understanding these factors in adults aged 18 to 65 who are generally healthy. Participants receive a single dose of ABBV-859 or a matching placebo by oral tablet or intravenous infusion on Study Day 1. The doses increase sequentially across different groups to assess the effects of different dose levels. This study uses a randomized and double-blind design, meaning neither participants nor researchers know who receives the drug or placebo. During the study, participants will be monitored up to 99 days for side effects, drug levels in the blood, and immune reactions. Assessments include physical exams, vital signs, blood tests, ECGs, and tracking of any adverse events. The study also collects measurements like maximum drug concentration, clearance, and antibody development to understand the drugs behavior and safety profile over time.
CONDITIONS
Brief Title
A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
